By Laura Serrano / September 22, 2021
“The key to reducing hospitalizations may be linked to effectively treating hypervolemia, which is a hypothesis consistent with data collected on ultrafiltration,” said Linda Hart, DNP, RN, ACNP-BC, AACC, and Nuwellis Clinical Education Manager. “Ultrafiltration is proven to safely, predictably and effectively remove excess fluid from the body, and acts as a mechanical diuretic to decongest patients.”
Ultrafiltration has shown a 53% reduction in risk of rehospitalization for heart failure. Data has also shown an 81% decrease in annual hospitalization rates when fluid overloaded patients are treated with ultrafiltration using Aquadex.
HF patients with diuretic resistance or renal insufficiency are particularly difficult to treat when hospitalized. A poster presented at HFSA by Dr. John Jefferies specifically highlighted that the combination of Blood Volume Analysis and ultrafiltration favored patient outcomes by adequately decongesting HF patients. Ultrafiltration is associated with higher fluid removal and weight loss, as well as reduced 90-day readmissions when compared with standard diuretic therapy.
If you missed this year’s conference, don’t worry: Nuwellis plans to be at HFSA 2022 next fall. Stay tuned for updates on our plans to collaborate with HFSA even further! In the meantime, we’re continuing our efforts to contribute to the HF field by supporting other conferences like this month’s UCLA Heart Failure Symposium.